Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)

Next Previous
X
Search
Trial Profile

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tezepelumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms NAVIGATOR
  • Sponsors Amgen; AstraZeneca

    • Most Recent Events

    • 01 May 2024 According to AstraZeneca media release, data from this trial will be presented at the American Thoracic Society (ATS) International Conference
    • 07 Nov 2023 Results of pooled analysis from pooled analysis of the PATHWAY and NAVIGATOR , published in the Annals of Internal Medicine
    • 19 Sep 2023 Results assessing the effect of tezepelumab versus placebo on additional lung function parameters in patients from NAVIGATOR published in the Advances in Therapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top